Welcome to our dedicated page for Aligos Therapeutics news (Ticker: ALGS), a resource for investors and traders seeking the latest updates and insights on Aligos Therapeutics stock.
Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical-stage biopharmaceutical company advancing novel therapies for chronic hepatitis B (CHB) and metabolic dysfunction-associated steatohepatitis (MASH). This page aggregates official press releases and verified news about the company’s clinical developments, research breakthroughs, and strategic partnerships.
Investors and industry professionals will find timely updates on ALGS’ pipeline candidates including oral capsid assembly modulators targeting viral suppression in CHB and THR-β agonists addressing liver fat reduction in MASH. The curated news collection provides essential context for understanding clinical trial progress, regulatory milestones, and scientific advancements.
Key content categories include updates on: Phase 1-3 clinical trials, collaborative research initiatives, regulatory communications, and therapeutic mechanism insights. All information is sourced from official company disclosures and reputable industry publications.
Bookmark this page for structured access to ALGS’ evolving scientific narrative. Check regularly for developments in oligonucleotide-based therapies and small molecule candidates progressing through clinical evaluation.
On April 11, 2023, Aligos Therapeutics (Nasdaq: ALGS) announced the presentation of seven posters at the EASL Congress 2023 in Vienna, occurring from June 21 to 24. The posters focus on five liver disease programs, showcasing data that highlights the company's advancements in addressing unmet medical needs in liver and viral diseases. Key presentations include data on Chronic Hepatitis B treatments involving compounds like CAM-E ALG-000184 and siRNA ALG-125755, as well as innovative approaches targeting Hepatocellular Carcinoma. Chairman & CEO Lawrence Blatt expressed optimism about these being potential best-in-class therapies. Detailed information will be made available on their corporate website post-conference.
Aligos Therapeutics (Nasdaq: ALGS) showcased positive results for its thyroid receptor-beta agonist candidate, ALG-055009, during the 15th Paris Hepatology Conference from March 27-29, 2023. The Phase 1 data revealed a favorable safety and pharmacokinetic profile in healthy volunteers and subjects with hyperlipidemia. The study demonstrated low variability and similar bioavailability for both liquid and gelcap formulations, which are set for a Phase 2 study with a regulatory filing anticipated in Q4 2023. These results indicate promising potential for addressing unmet medical needs in liver and viral diseases.
Aligos Therapeutics (Nasdaq: ALGS) announced significant advancements in its drug development pipeline for NASH, COVID-19, and CHB diseases, highlighting progress in clinical trials and positive data from candidate ALG-055009. The company reported a cash balance of $125.8 million as of December 31, 2022, down from $205.8 million in 2021, but sufficient to fund operations through the end of 2024. Net losses decreased to $21.9 million for Q4 2022, compared to $37.7 million in Q4 2021, and annual losses were $96.0 million, down from $128.3 million.
The firm anticipates key data readouts throughout 2023, which could drive shareholder value.
Aligos Therapeutics, Inc. (Nasdaq: ALGS) announced it will report its fourth quarter 2022 financial results on March 9, 2023, after U.S. market close. The company specializes in developing therapeutics targeting nonalcoholic steatohepatitis (NASH) and viral diseases, aiming to be a leader in liver disease treatment. Founded in 2018, Aligos is focusing on advancing its pipeline of potentially best-in-class molecules. The press release includes forward-looking statements, highlighting risks such as drug development uncertainties and capital resource sufficiency.
FAQ
What is the current stock price of Aligos Therapeutics (ALGS)?
What is the market cap of Aligos Therapeutics (ALGS)?
